EMT Cancer Research Results

EMT, Epithelial-Mesenchymal Transition: Click to Expand ⟱
Source:
Type:
Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin.
EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin).
EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis.
Scientific Papers found: Click to Expand⟱
77- QC,  EGCG,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, CD44+ - in-vitro, NA, CD133+ - in-vitro, NA, PC3 - in-vitro, NA, LNCaP
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, eff↑, CSCs↓, TumCG↓, tumCV↓,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2/PTGS2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1/CCND1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp/ABCB1↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
1490- RES,    Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
- Review, Var, NA
TumCCA↑, ROS↑, Ca+2↑, MMP↓, ATP↓, TOP1?, P53↑, p53 Wildtype∅, Akt↓, mTOR↓, EMT↓, *BioAv↓,
2687- RES,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, NA, NA - Review, AD, NA
NF-kB↓, P450↓, COX2/PTGS2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, eff↑, HK2↓, ROS↑, MMP↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,
3081- RES,    Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
- Review, CRC, NA
NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,
3078- RES,    The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment
- Review, Pca, NA
*ROS↓, ROS↑, DNAdam↑, Apoptosis↑, Hif1a↑, Casp3↑, Casp9↑, Cyt‑c↑, Dose↝, MMPs↓, MMP2↓, MMP9↓, EMT↓, E-cadherin↑, N-cadherin↓, AR↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
4668- RES,    Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation
- in-vitro, NPC, NA
ROS↑, MMP↓, CSCs↓, P53↑, EMT↓,
4663- RES,    Exploring resveratrol’s inhibitory potential on lung cancer stem cells: a scoping review of mechanistic pathways across cancer models
- Review, Var, NA
*antiOx↑, *Inflam↓, *chemoPv↑, CSCs↓, Wnt↓, β-catenin/ZEB1↓, NOTCH↓, PI3K↓, Akt↓, mTOR↓, GSK‐3β↝, Snail↓, HH↓, p‑GSK‐3β↓, N-cadherin↓, EMT↓, CD133↓, CD44↓, ALDH1A1↓, OCT4↓, SOX4↓, Shh↓, Smo↓, Gli1↓, GLI2↓,
101- RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, Snail↓, N-cadherin↓, E-cadherin↑, TumCI↓, TumMeta↓,
105- RES,  QC,    The Effect of Resveratrol and Quercetin on Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem Cell
- in-vitro, Pca, PANC1
N-cadherin↓, TNF-α↓, ACTA2↓, EMT↓, CD133↓, CSCs↓,
102- RES,    Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway
- in-vitro, PC, MIA PaCa-2
HH↓, PTCH1↓, Smo↓, HH↓, EMT↓, PI3K/Akt↓, NF-kB↓, TumCP↓, Apoptosis↑, ChemoSen↑,
878- RES,    Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
- vitro+vivo, CRC, LoVo
TumMeta↓, E-cadherin↑, Vim↓, TGF-β↓, SMAD2↓, EMT↓, SMAD3↓,
7150- RES,    Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity
- Review, Var, NA
AntiTum↑, PI3K↓, Akt↓, *AntiAge↑, *SIRT1↑, *lipid-P↓, *ROS↓, *BioAv↓, *NRF2↑, *HO-1↑, SOD↑, HDAC1↓, PTEN↑, P53↑, TumCCA↑, TumCI↓, TumMeta↓, EMT↓, MMPs↓, MMP9↓, angioG↓, VEGF↓, EGFR↓, FGF21↓, HIF-1↓, *neuroP↑, *cardioP↑, BMPs↑, ROS↑, Vim↓, N-cadherin↓, MMP3↓, MMP13↓, E-cadherin↑, Ki-67↓,
1745- RosA,    Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications
- Review, Var, NA - Review, AD, NA
ChemoSideEff↓, ChemoSen↑, antiOx↑, MMP2↓, MMP9↓, p‑AMPK↑, DNMTs↓, tumCV↓, COX2/PTGS2↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, Casp3↑, Casp9↓, ROS↓, GSH↑, ERK↓, Akt↓, ROS↓, NF-kB↓, p‑IκB↓, p50↓, p65↓, neuroP↑, Dose↝,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3006- RosA,    Rosmarinic acid attenuates glioblastoma cells and spheroids’ growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229
TumCG↓, EMT↓, SIRT1↓, FOXO1↓, NF-kB↓, angioG↓, ROS↓, PTEN↓, PI3K↓, Akt↓, *Inflam↓, *cardioP↑, *hepatoP↑, *neuroP↑, Warburg↓,
3003- RosA,    Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2/PTGS2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, FOXM1↓, cycD1/CCND1↓, CDK4↓, MMP9↓, HDAC2↓,
3037- RosA,    Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation
- in-vitro, Oral, SCC9 - in-vitro, Oral, HSC3
survivin↓, AntiCan↑, Vim↓, Snail↓, SOX9↓, EMT↓, MMP2↓, MMP9↓, P-gp/ABCB1↓, TumCG↓, ROS↑, MMP↓, GSH↓, P-gp/ABCB1↓, ATP↓,
4904- Sal,  CUR,    Co-delivery of Salinomycin and Curcumin for Cancer Stem Cell Treatment by Inhibition of Cell Proliferation, Cell Cycle Arrest, and Epithelial–Mesenchymal Transition
CSCs↓, TumCCA↑, EMT↓, other↝, TumAuto↑, Iron↑, Ferroptosis↑, BioAv↓, ROS↑, lipid-P↑, GPx4↓, eff↑,
5127- Sal,    Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway
- in-vitro, Ovarian, NA
TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Wnt↓, β-catenin/ZEB1↓, TumCP↓, TumCMig↓, EMT↓,
1134- SANG,    Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
Hif1a↓, EMT↓, Snail↓, PI3K↓, Akt↓, SMAD2↓, SMAD3↓,
6441- SAO,    Sandalwood Album Oil as a Botanical Therapeutic in Dermatology
- Review, PSA, NA
*Inflam↓, *eff↑, *5LO↓, *DPPH↓, *hepatoP↑, *ROS↓, *PGE2↓, *IL1β↓, *IL17↓, *PDE4↓, *tyrosinase↓, *AntiFungal↑, angioG↓, TumCG↓, DNAdam↑, *Snail↑, *Twist↑, *Vim↑, *EMT↓, *toxicity↓,
4485- Se,    Selenium stimulates the antitumour immunity: Insights to future research
- Review, NA, NA
*antiOx↑, chemoPv↑, ROS↑, Imm↑, selenoP↑, *IL2↑, *IL4↑, *TNF-α↓, *TGF-β↓, *EMT↓, Risk↓, *GPx↑, *TrxR↑,
1135- Selenate,    Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation
- in-vitro, CRC, DLD1
EMT↑, Akt↑, Twist↑, Vim↑, E-cadherin↓,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2/KDR/Flk1↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
1136- SFN,    Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells
- in-vitro, Lung, NA - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Snail↓, ERK5↑, EMT↓,
1014- SFN,    Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
Zeb1↓, Apoptosis↑, Fibronectin↓, CLDN1↓, β-catenin/ZEB1↓, EMT↓,
110- SFN,    Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway
- in-vivo, PC, NA
HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, VEGF↓, PDGFRA↓, EMT↓, Zeb1↓, Bcl-2↓, XIAP↓, E-cadherin↑, OCT4↓, Nanog↓, TumCG↑,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2/PTGS2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2/PTGS2↝, MMP2↝, MMP9↝,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2/KDR/Flk1↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27/CDKN1B↑, DNMT1↓, DNMT3A↓, cycD1/CCND1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT/TERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2/PTGS2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31/PECAM-1↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2/PTGS2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1/SREBF1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2/PTGS2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2196- SK,    Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species
- Review, Var, NA
*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
5075- SSE,    Sodium selenite inhibits proliferation and metastasis through ROS‐mediated NF‐κB signaling in renal cell carcinoma
- vitro+vivo, RCC, 786-O
TumCP↓, TumCMig↓, Apoptosis↑, ROS↑, NF-kB↓, eff↓, E-cadherin↑, cl‑Casp3↑, VEGF↓, MMP9↓, EMT↓, MMP↓, mtDam↑, BAX↑, Bcl-2↓,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,
6436- T4O,    Terpinen-4-ol suppresses proliferation and motility of cutaneous squamous cell carcinoma cells by enhancing calpain-2 expression
- in-vitro, Melanoma, A431
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, AntiTum↑, cal2↑, cl‑β-catenin/ZEB1↑, cl‑Casp12↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, BAX↑, TumCCA↑, selectivity↑, N-cadherin↓, E-cadherin↑, Ki-67↓, PCNA↑,
1138- TQ,    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,

Showing Research Papers: 251 to 300 of 322
Prev Page 6 of 7 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 322

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Ferroptosis↑, 1,   GPx4↓, 2,   GSH↓, 2,   GSH↑, 2,   GSTA1↑, 1,   HO-1↑, 3,   Iron↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   NQO1?, 1,   NRF2↓, 1,   NRF2↑, 2,   mt-OXPHOS↓, 1,   ROS?, 1,   ROS↓, 4,   ROS↑, 19,   selenoP↑, 1,   SOD↓, 1,   SOD↑, 1,   SOD1↓, 1,   SOD2↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 6,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 12,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑ACLY↓, 1,   AKT1↓, 1,   AMPK↓, 1,   AMPK↑, 1,   p‑AMPK↑, 1,   cMyc↓, 4,   FABP4↑, 1,   FGF21↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 1,   GlutMet↓, 1,   Glycolysis↓, 3,   HK2↓, 2,   HMG-CoA↓, 1,   lactateProd↓, 2,   PFK↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 3,   POLD1↓, 1,   PPARα↑, 1,   PPARγ↑, 1,   SIRT1↓, 3,   SIRT1↑, 1,   SIRT2↓, 1,   SREBP1/SREBF1↓, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 14,   Akt↑, 1,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 13,   BAX↑, 8,   Bcl-2↓, 11,   Bcl-xL↓, 3,   BIM↓, 1,   Casp↑, 2,   Casp1↓, 1,   Casp10↑, 1,   cl‑Casp12↑, 1,   Casp3↑, 10,   cl‑Casp3↑, 3,   Casp7↑, 3,   Casp8↑, 2,   Casp9↓, 1,   Casp9↑, 5,   p‑Chk2↑, 1,   CK2↓, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 5,   DR5↑, 2,   Fas↑, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 2,   Mcl-1↓, 1,   MDM2↓, 1,   Myc↓, 1,   p27/CDKN1B↑, 2,   p38↑, 1,   p‑p38↓, 1,   RIP1↑, 1,   survivin↓, 6,   Telomerase↓, 1,   TNFR 1↑, 1,   TRAIL↑, 1,   TRAILR↑, 1,   TUNEL↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 2,   SOX9↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ac‑H3↑, 1,   HATs↓, 1,   HATs↑, 2,   other↓, 1,   other↝, 1,   tumCV↓, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   HSP27↓, 2,   IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↓, 1,   BNIP3↑, 1,   LC3II↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DFF45↑, 1,   DNAdam↑, 4,   DNMT1↓, 2,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↑, 8,   p53 Wildtype∅, 1,   cl‑PARP↑, 3,   PCNA↓, 2,   PCNA↑, 1,   TP53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK1↑, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycD1/CCND1↑, 1,   P21↓, 1,   P21↑, 5,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   ALDH1A1↓, 4,   CD133↓, 4,   CD44↓, 5,   CSCs↓, 12,   Diff↓, 1,   EMT?, 1,   EMT↓, 45,   EMT↑, 1,   ERK↓, 3,   ERK↑, 1,   p‑ERK↓, 1,   ERK5↑, 1,   FGF↑, 1,   FOXM1↓, 1,   FOXO1↓, 1,   FOXO4↓, 1,   Gli1↓, 5,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   GSK‐3β↝, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 5,   HDAC1↓, 1,   HDAC2↓, 1,   HH↓, 5,   IGF-1↓, 1,   IGFBP3↓, 1,   IGFBP3↑, 1,   mTOR↓, 9,   Nanog↓, 4,   Nestin↓, 1,   NOTCH↓, 3,   NOTCH1↓, 2,   OCT4↓, 3,   PDGFRA↓, 1,   PI3K↓, 11,   PTCH1↓, 1,   PTEN↓, 1,   PTEN↑, 3,   Shh↓, 4,   Smo↓, 4,   SOX2↓, 1,   Src↓, 1,   STAT3↓, 5,   TCF↓, 2,   TOP1?, 1,   TOP2↓, 1,   TumCG↓, 12,   TumCG↑, 1,   Wnt↓, 6,  

Migration(tgid=13) ⓘ

ACTA2↓, 1,   CA↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   cal2↑, 1,   CD31/PECAM-1↓, 1,   CLDN1↓, 1,   COL1↓, 1,   COL3A1↓, 1,   CXCL12↓, 1,   E-cadherin↓, 3,   E-cadherin↑, 20,   FAK↓, 3,   Fibronectin↓, 2,   GIT1↓, 1,   GLI2↓, 2,   ITGB1↓, 1,   Ki-67↓, 6,   LEF1↓, 2,   MALAT1↓, 1,   MARK4↓, 1,   miR-203↑, 1,   MMP13↓, 2,   MMP2↓, 13,   MMP2↝, 1,   MMP3↓, 1,   MMP7↓, 3,   MMP9↓, 15,   MMP9↝, 1,   MMPs↓, 5,   MUC1↑, 1,   N-cadherin↓, 12,   PDGF↓, 1,   RAGE↓, 1,   RHBDD1↓, 1,   RIP3↑, 1,   Slug↓, 6,   SMAD2↓, 4,   SMAD3↓, 4,   Snail↓, 12,   SOX4↓, 1,   TGF-β↓, 7,   TIMP1↑, 1,   TSP-1↑, 1,   TumCI↓, 16,   TumCMig↓, 13,   TumCP↓, 10,   TumMeta↓, 9,   Twist↓, 1,   Twist↑, 1,   uPA↓, 3,   Vim?, 1,   Vim↓, 14,   Vim↑, 1,   Zeb1↓, 7,   ZO-1↑, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 8,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 8,   ATF4↑, 1,   EGFR↓, 6,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 12,   Hif1a↑, 1,   VEGF↓, 16,   VEGFR2/KDR/Flk1↓, 3,  

Barriers & Transport(tgid=15) ⓘ

NHE1↓, 1,   P-gp/ABCB1↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↑, 1,   COX2/PTGS2↓, 7,   COX2/PTGS2↝, 1,   CRP↓, 1,   CXCR4↓, 3,   ICAM-1↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 4,   IL6↑, 1,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 4,   p‑IκB↓, 1,   MDSCs↓, 1,   NF-kB↓, 11,   p50↓, 1,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 1,   Th1 response↑, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 4,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 1,   BioAv↝, 2,   ChemoSen↑, 7,   ChemoSen⇅, 1,   Dose↝, 4,   eff↓, 2,   eff↑, 12,   eff↝, 2,   Half-Life↓, 1,   Half-Life↝, 1,   MDR1↓, 2,   P450↓, 3,   RadioS↑, 3,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 4,   BMPs↑, 1,   CRP↓, 1,   EGFR↓, 6,   FOXM1↓, 1,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 1,   IL6↓, 4,   IL6↑, 1,   Ki-67↓, 6,   Myc↓, 1,   PD-L1↓, 1,   PSA↓, 1,   RAGE↓, 1,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 3,   cardioP↑, 3,   chemoP↑, 3,   chemoPv↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 2,   neuroP↑, 2,   radioP↑, 1,   Risk↓, 1,   toxicity?, 1,   toxicity↝, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 342

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 5,   DPPH↓, 1,   GPx↑, 1,   HO-1↑, 1,   Keap1↓, 1,   lipid-P↓, 1,   NRF2↑, 3,   ROS↓, 8,   TrxR↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   SIRT1↑, 3,  

Cell Death(tgid=5) ⓘ

JNK↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 2,   EMT↑, 1,   HDAC↓, 1,   HDAC3↓, 1,   tyrosinase↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   Ki-67↓, 1,   Snail↑, 1,   TGF-β↓, 1,   TIMP1↓, 1,   Twist↑, 1,   Vim↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   HMGB1↓, 1,   IL17↓, 1,   IL1β↓, 2,   IL2↑, 1,   IL4↑, 1,   IL6↓, 1,   IL8↓, 1,   Inflam?, 1,   Inflam↓, 6,   NF-kB↓, 1,   PGE2↓, 2,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   cardioP↑, 3,   chemoPv↑, 1,   hepatoP↑, 2,   memory↑, 2,   neuroP↑, 5,   PDE4↓, 1,   toxicity↓, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,  
Total Targets: 56

Scientific Paper Hit Count for: EMT, Epithelial-Mesenchymal Transition
19 Curcumin
17 Resveratrol
15 Quercetin
13 Honokiol
10 Sulforaphane (mainly Broccoli)
9 Ashwagandha(Withaferin A)
9 EGCG (Epigallocatechin Gallate)
9 Fisetin
9 Thymoquinone
6 Astragalus
6 Berberine
6 Luteolin
6 Metformin
6 Piperine
6 Rosmarinic acid
5 Apigenin (mainly Parsley)
5 Betulinic acid
5 Chrysin
5 Emodin
5 Eugenol
5 Silymarin (Milk Thistle) silibinin
4 Alpha-Lipoic-Acid
4 Baicalein
4 Propolis -bee glue
4 Chlorogenic acid
4 Inositol
4 Pterostilbene
4 Shikonin
3 Artemisinin
3 Atorvastatin
3 5-fluorouracil
3 Cyclopamine
3 salinomycin
3 Genistein (soy isoflavone)
3 Ferulic acid
3 Fucoidan
3 Garcinol
3 HydroxyTyrosol
3 Lycopene
3 Nimbolide
3 Piperlongumine
3 Urolithin
2 Anethole/trans-Anethole
2 Cisplatin
2 Astaxanthin
2 Beta-Caryophyllene
2 brusatol
2 Capsaicin
2 Cannabidiol
2 Celecoxib
2 Centella asiatica / Gotu kola → asiaticoside
2 Crocetin
2 Radiotherapy/Radiation
2 Deguelin
2 Dandelion Root
2 Disulfiram
2 Ellagic acid
2 Sorafenib (brand name Nexavar)
2 Ginkgetin
2 Grapeseed extract
2 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
2 Isoliquiritigenin
2 isoflavones
2 isoorientin
2 isoquercitrin
2 Naringin
2 Phenethyl isothiocyanate
2 Vitamin C (Ascorbic Acid)
2 Vitamin D3
2 VitK3,menadione
1 1,8-Cineole
1 Anthocyanins
1 Allicin (mainly Garlic)
1 alpha Linolenic acid
1 DTS(dibenzyl trisulphide) from Anamu
1 Aspirin
1 Baicalin
1 Berbamine
1 Biochanin A
1 Brucea javanica
1 Boron
1 Caffeic acid
1 Carnosic acid
1 Cucurbitacin
1 Oxaliplatin
1 Dichloroacetate
1 Docosahexaenoic Acid
1 immunotherapy
1 Copper and Cu NanoParticles
1 Ginkgo biloba-EGb 761
1 Eurycomanone
1 Cinnamon
1 Evodiamine
1 Shilajit/Fulvic Acid
1 Gallic acid
1 Paclitaxel/Taxol
1 Ginkgolide B
1 Proanthocyanidins
1 Hydrogen Gas
1 Chemotherapy
1 Hydroxycinnamic-acid
1 Hyperoside
1 Ivermectin
1 Isovitexin
1 Juglone
1 Licorice
1 Lactoferrin
1 methotrexate
1 Magnolol
1 Myricetin
1 Niclosamide (Niclocide)
1 Oleocanthal
1 Plumbagin
1 Psoralidin
1 Sanguinarine
1 α-Santalol/Sandalwood oil
1 Selenium
1 Selenate
1 Gemcitabine (Gemzar)
1 Selenite (Sodium)
1 statins
1 Citric Acid
1 Terpinen-4-ol / Tea Tree Oil
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Vitamin K2
1 Vitexin
1 Zinc
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:96  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page